Abstract: A method of transmitting signals from a base station towards user terminals in a cellular communication system. The method includes generating diversity signals, wherein at least one of the diversity signals is subjected to a selectively variable RF phase shift. Specifically, a set of radio link quality indicators is determined at the base station, wherein each radio link quality indicator is representative of the quality of the radio link between the base station and a respective one of the user terminals. The set of radio link quality indicators is used to generate an aggregated radio quality indicator, which in turn is used to selectively vary the variable RF phase shift. For example, the phase shift may be selected, which optimizes the aggregated radio quality indicator.

Abstract: The invention relates to a method for dynamic automation, in which collaborative elements, such as humans and mobile robots, but also machines, co-operate, in order to carry out tasks as efficiently as possible. Each of said collaborative elements carries out a part of a working process which exploits the concept of collaboration the most in terms of efficiency, flexibility, quality and performance. The invention also relates to a control system for carrying out said method. The inventive method can be applied in logistics, especially storage logistics, such as commissioning.

Abstract: In a method of scheduling transmission services over a high speed packet access communication link such as a HSDPA and/or a HSUPA link a list of queues is created for transmission services to be provided over the link. The queues, which include both Real Time and Non Real Time queues, are allotted respective service priorities based e.g. on a channel quality indicator and/or a Quality of Service indicator to produce an ordered list of queues based on the service priorities. The link resources needed for serving at least one set of queues having higher priorities in the ordered list are estimated and a check is made. If these resources are available, the set of queues having higher priorities in the ordered list are served. If the resources required are not available, at least one queue is removed from the ordered list of queues.

Abstract: Process for preparing a compound of formula (I), or a salt thereof, comprising reacting of a compound of formula (II) wherein X and R are as herein defined; with a compound of formula (III) NH2OZ??(III) wherein Z is a hydroxy protecting group, in presence of a catalyst, to obtain a compound of formula (IV), or a salt thereof, removing the hydroxyl protecting group to obtain a compound of formula (V), or a salt thereof; converting a compound of formula (V), or a salt thereof, into a compound of formula (I), or a salt thereof; and, if desired, converting a compound of formula (I) into a salt thereof, or vice versa.

Abstract: A process for preparation of a compound of formula (I), both as the isomeric mixture and individual isomers, wherein Q is ?CR8— or ?N—; each R1, R2, R3, R4 is independently selected from hydrogen, halogen, hydroxy; nitro; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen or C1-C6 alkoxy; phenyl-C1-C6 alkyl; phenyl-C1-C6 alkoxy; and —N(RaRb) wherein each Ra and Rb is independently hydrogen or C1-C6 alkyl or Ra and Rb, taken together with the nitrogen atom they are linked to, form a saturated heterocyclic ring; and each R5, R6, R7, R8 is independently selected from hydrogen, halogen, hydroxy; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen; C1-C6 alkyl-carbonyl, C1-C6 alkoxy-carbonyl, and oxazol-2-yl; comprising converting a compound of formula (IV), to said compound of formula (I), in the presence of a catalyst, if necessary in an organic solvent.

Abstract: A novel process for the preparation of tolterodine, i.e. (R)—N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.

Abstract: A novel process for the preparation of tolterodine, i.e. (R)—N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.

Abstract: A novel process prepares tolterodine, i.e. (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation. Tolterodine free base may be prepared by reacting diisopropyl-(3-phenyl-3-p-tolyloxy-propyl)-amine and 60% aqueous sulfuric acid for three hours under stirring at room temperature. The reaction mixture is then poured over ice/water and then alkalized with 50% NaOH.

Abstract: A process for the preparation of a compound of formula (I) or a salt thereof wherein R is an amino, nitro or —NHCOR1 group, wherein R1 is C1-C6 alkyl or phenyl optionally substituted by a —O—(CH2)n-phenyl group, wherein n is an integer of 1 to 6; comprising reacting a compound of formula (II) or a salt thereof, both as the individual isomer and as an isomeric mixture, wherein R is as defined above; with a dehydrating agent, if necessary in the presence of an organic solvent, and optionally in the presence of a basic agent; and, if desired, converting a compound of formula (I) to another compound of formula (I) or a salt thereof.

Abstract: A process for preparation of a compound of formula (I), or a salt thereof, both as individual isomer and as mixtures thereof, wherein each of A and B is independently aryl or heteroaryl optionally substituted with 1 to 4 substituents; and R and R1, which can be the same or different, are hydrogen, C1-C6 alkyl or an amino-protecting group; comprising the reaction of a compound (II) wherein A and B are as defined above, with a compound (III) wherein each of R and R1 is independently C1-C6 alkyl or an amino-protecting group; and X is a leaving group; in the presence of a basic agent; and, if desired the conversion of a compound (I) to another compound (I); and/or, if desired, the separation of an isomeric mixture of a compound (I) into the individual isomers; and/or, if desired, the conversion of a compound (I) to a salt thereof.

Abstract: A process for preparation of a compound of formula (I), both as the isomeric mixture and individual isomers, wherein Q is ?CR8— or ?N—; each R1, R2, R3, R4 is independently selected from hydrogen, halogen, hydroxy; nitro; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen or C1-C6 alkoxy; phenyl-C1-C6 alkyl; phenyl-C1-C6 alkoxy; and —N(RaRb) wherein each Ra and Rb is independently hydrogen or C1-C6 alkyl or Ra and Rb, taken together with the nitrogen atom they are linked to, form a saturated heterocyclic ring; and each R5, R6, R7, R8 is independently selected from hydrogen, halogen, hydroxy; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen; C1-C6 alkyl-carbonyl, C1-C6 alkoxy-carbonyl, and oxazol-2-yl; comprising converting a compound of formula (IV), to said compound of formula (I), in the presence of a catalyst, if necessary in an organic solvent.

Abstract: A process for the preparation of angiotensin II antagonists and novel intermediates useful for the synthesis thereof.

Abstract: A process for the preparation of 6-methyl-4-(R)-phenyl-chroman-2-one and 6-methyl-4-(S)-phenyl-chroman-2-one, intermediates for the synthesis of tolterodine and its (S) enantiomer, by reaction of 6-methyl-coumarin with phenylboronic acids, esters and derivatives thereof, in the presence of chiral catalysts.

Abstract: A syringe (100) has a syringe body (1) hollow on the inside, a plunger (4) slidable in the syringe body (1) and provided at the rear with a shaft (41) that can be operated manually, an injection needle (2) engageable to the front end (13) of the syringe body (1) with a needle-carrier (20), and a guard mechanism (200) having a sleeve (5), a spring (7) and a abutment member (8) for the spring. The abutment member (8) is mounted in the head of the syringe and the spring (7) is disposed between the sleeve (5) and the abutment member (8). The sleeve (5) can pass from a retracted position of use, wherein the needle (2) protrudes forward therefrom to a forward position of safety, wherein it covers the needle.

Abstract: A novel process for the preparation of tolterodine, i.e. (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, in the racemic form, as well as intermediates useful for its preparation.

Abstract: The invention relates to a method for dynamic automation, in which collaborative elements, such as essentially humans and mobile robots, but also machines, co-operate, in order to carry out tasks as efficiently as possible. Each of said collaborative elements carries out exactly the part of a working process which exploits the concept of collaboration the most in terms of efficiency, flexibility, quality and performance. In each working step, the collaborative elements (KE(I), KE(II)) are guided by a control system (2) into an execution zone (3) where they carry out the working step by means of communication media (4) static resources (5) and possibly machines (KE(III)). The next working process, the next working step, and the distribution of the resources in the area (1) are dynamically determined by the control system, each allocation being carried out at the last possible moment, additionally taking into account the current state of the collaborative system.

Abstract: A butterfly needle for venipuncture includes a body with two protruding flexible tongues that can be bent by manual gripping by the user from a diverging position to a converging position, and a needle mounted axially in the fore end of a needle-carrier which a tail protruding rearward from the body to couple with the connection of a flexible tube destined to be connected to a syringe or a bottle. The needle-carrier is mounted axially slidable in the body to pass from a forward position of use wherein the needle protrudes forward from the body to perform the injection to a retracted position of safety wherein the needle is protected inside the body, there being provided guide elements able to guide the axial movement of the needle-carrier inside the body and end-of-stroke and locking elements able to lock the needle-carrier in the advanced position and in the retracted position.

Abstract: A safety catheter includes a body having an axial channel communicating with a sheath for administration of fluids, a guide needle insertable, though the channel of the body, into the sheath to guide it during insertion into a patient's body, and a guide needle body, supporting the guide needle, insertable into the catheter body and provided with at least one seat for coupling with medical instruments, the guide needle being mounted slidably in the catheter body to be able to pass from a forward working position, wherein the guide needle protrudes forward from the catheter body, to a retracted safety position, wherein the guide needle is protected inside the catheter body, locking elements disposed in the guide needle, cooperating with complementary stop elements disposed in the catheter body, to lock the guide needle body respectively in the forward working and the retracted safety positions.

Abstract: A process for the preparation of 6-methyl-4-(R)-phenyl-chroman-2-one and 6-methyl-4-(S)-phenyl-chroman-2-one, intermediates for the synthesis of tolterodine and its (S) enantiomer, by reaction of 6-methyl-coumarin with phenylboronic acids, esters and derivatives thereof, in the presence of chiral catalysts.

Abstract: An apparatus (100) for collecting blood samples comprises a sleeve (1) having a substantially cylindrical body (10), hollow on the inside, defining an inner chamber (11) open at the front and rear, a needle assembly (5) comprising a needle-carrier (50) which carries at its opposite ends a first external needle (51) designed to be inserted into the patient's vein and a second internal needle (52) designed to engage in a vacutainer-type test tube, and a safety device (7) having a substantially cylindrical hollow body (70) defining an inner chamber (71) able to receive the vacutainer-type test tube.